Abstract
The nuclear factor I (NFI) family members, especially NFIA and NFIB, play essential roles in cancers. The roles of NFIA and NFIB in esophageal squamous cell carcinoma (ESCC) and esophagogastric junction adenocarcinoma (EJA) remain poorly known. This study aimed to determine the expression of NFIA and NFIB in ESCC and EJA and elucidate their prognostic significance. The expression of NFIA and NFIB was examined in 163 ESCC samples and 26 EJA samples by immunohistochemistry. The results showed that high NFIA expression correlated significantly with poor differentiation, lymph node metastasis, and advanced TNM stage in patients with ESCC. High NFIB expression only correlated with poor differentiation in patients with ESCC. Survival analysis showed that NFIA but not NFIB associated with short overall survival (OS) and disease‐free survival (DFS) of patients with ESCC. On the other hand, high NFIB expression correlated with lymph node metastasis, advanced TNM stage, and short OS and DFS in patients with EJA. Finally, multivariate analysis demonstrated that high NFIA expression was an independent prognostic factor for ESCC. Taken together, these results demonstrated that NFIA and NFIB could serve as prognostic indicators for ESCC and EJA, respectively.
Highlights
Esophageal squamous carcinoma (ESCC) accounts for more than 90% of esophageal cancer (EC), which is one of the most prevalent cancers in Africa and Asia [1]
The results showed that high NFIA expression correlated with poor differentiation, lymph node metastasis, and short overall survival (OS) and disease-free survival (DFS) in patients with ESCC
These results revealed that NFIA was highly expressed in ESCC tissues and high NFIA expression correlated with poor differentiation, lymph node metastasis, and advanced TNM stage in ESCC
Summary
Esophageal squamous carcinoma (ESCC) accounts for more than 90% of esophageal cancer (EC), which is one of the most prevalent cancers in Africa and Asia [1]. Most patients die within 1 year after diagnosis, and the five-year survival rate is only 8% to 20% [2]. Esophagogastric junction adenocarcinoma (EJA) is defined as the carcinoma that across the esophagogastric junction line, including both distal esophageal adenocarcinoma and proximal gastric cancer [3]. Accumulating studies reveal that EJA is different from gastric and esophageal. NFIA and NFIB in Esophageal Cancer adenocarcinoma in molecular features, pathological evolution, and clinical behavior [4]. The five-year survival rate of EJA is as low as 10–15% [6].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
